Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
g 15 Introduction Adenosine monophosphate cAMP is a general
2024-07-26

Introduction Adenosine 3′,5′-monophosphate (cAMP) is a general-purpose signaling molecule present in most branches of life. Intracellular cAMP levels control diverse cellular functions. In bacteria, cAMP regulates metabolism by activation of the catabolite activator protein (CAP), also known as cAM
-
tmn The potential use of derivatives belonging to this serie
2024-07-26

The potential use of derivatives belonging to this series as therapeutic agents mostly depends on their pharmacokinetics and pharmacodynamics. The pharmacokinetic phase includes absorption, distribution, metabolism and excretion (ADME) of the studied compounds. Therefore, preliminary data for theore
-
A more versatile cellular delivery system for adenosine was
2024-07-26

A more versatile cellular delivery system for adenosine was generated by engineering mouse embryonic stem cells to lack both MHY1485 of Adk (Fedele et al., 2004). Using a step-wise differentiation protocol (Okabe et al., 1996) Adk−/− ES cells were differentiated into transplantable adenosine-releasi
-
Previous studies have demonstrated the presence of soluble N
2024-07-26

Previous studies have demonstrated the presence of soluble NTPDases, 5′-nucleotidase and adenosine deaminase in rat blood serum as well as in human blood (Doleski et al., 2016; Oses et al., 2004; Yegutkin, 1997; Yegutkin et al., 2007). In addition, our earlier reports have shown that these membrane-
-
k145 Given that there are substitutions between Anc and the
2024-07-25

Given that there are 132 substitutions between βAnc and the human β subunit, we wondered whether βAnc could replace the human β subunit in hybrid AChRs formed from ancestral and human subunits. We first confirmed that the β subunit is required for expression of human AChRs in HEK293 k145 by co-tran
-
There are several reports about the expression of AChRs
2024-07-25

There are several reports about the expression of AChRs and their modulation to osteogenic factors in osteoblasts (Rothem et al., 2011, Sato et al., 2010, Walker et al., 2001). The normal osteocytic MLO-Y4 NU 1025 sale expressed multiple subtypes, which was demonstrated by the detection of M1, M2, M
-
Fig A shows a schematic representation of histological
2024-07-25

Fig. 2A shows a schematic representation of histological results according to the Franklin and Paxinos Mouse Brain Atlas (2001). The black circles represent the sites of drug infusion that were on-target within the amygdala. Gray circles represent the animals that had infusion locations outside the
-
br Conclusion There have been multiple clinical trials and
2024-07-25

Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi
-
In conclusion AXL overexpression preexisted in a subgroup of
2024-07-25

In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
-
Our sample is representative of mRCC treated with
2024-07-25

Our sample is representative of mRCC treated with sunitinib. However, the results from CCC setting have limited inference due to small exploratory sample (n = 51). Additionally, the significance of survival differences in CCC according to AXL staining is tangential. Unfortunately, we were unable to
-
Accumulating data suggest that ROS trigger autophagy but in
2024-07-25

Accumulating data suggest that ROS trigger autophagy but, in turn, autophagy reduces ROS levels [23]. Our results are in agreement because 27-OH mediated autophagy induction interms of LC3 II formation and Beclin 1 protein expression was suppressed by treating the promonocytic cells with the antioxi
-
Accumulating data suggest that ROS trigger autophagy but in
2024-07-25

Accumulating data suggest that ROS trigger autophagy but, in turn, autophagy reduces ROS levels [23]. Our results are in agreement because 27-OH mediated autophagy induction interms of LC3 II formation and Beclin 1 protein expression was suppressed by treating the promonocytic cells with the antioxi
-
In many cells AR mediated activation
2024-07-25

In many estriol α1-AR mediated activation of PLC has been shown to be the downstream process for NA-induced signalling. The activated PLC initiates subsequent signalling by breakdown of PIP2 to IP3 and DAG (Fisher and Agranoff, 1987) and the process continues. To confirm if such mechanism exists in
-
Losmapimod In this study we found
2024-07-25

In this study, we found that ACL silencing is sufficient to impair myoblast differentiation and that this effect is accompanied by a decrease in MYOD early in the myogenic process and by a subsequent decline in fast MyHC protein Losmapimod at a later stage of differentiation (Figure 4J). Furthermor
-
br Nanoparticle Conjugated Topoisomerase Inhibitors The safe
2024-07-25

Nanoparticle-Conjugated Topoisomerase Inhibitors The safety and efficacy of topotecan administered as LDM or MTD have been evaluated in several preclinical studies and a few clinical trials whose results showed that there can be significant adverse effects likely precluding its use in patients [5
15948 records 119/1064 page Previous Next First page 上5页 116117118119120 下5页 Last page